Research output per year
Research output per year
Personal profile
About Me
Experienced biotechnology executive, with demonstrated history as CEO, Chairman and Board member. Over twenty years as an executive in the biotechnology industry which include 12 years as President & CEO of Protalix Biotherapeutics, leading it to FDA drug approval (Elelyso for treating Gaucher Disease) and Wall Street listing (NYSE). Skilled in drug developmemt, privete and public market financing, FDA, GMP production and clinical trials. Strong business development and strategic planning professional. Ph.D. in Biochemistray & Molecular Biology from the Weizmann Institute of Science as well as an MBA from Bar Ilan university.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
… → Jan 1996
Fingerprint
Dive into the research topics where David Aviezer is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
-
Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease
Kizhner, T., Azulay, Y., Hainrichson, M., Tekoah, Y., Arvatz, G., Shulman, A., Ruderfer, I., Aviezer, D. & Shaaltiel, Y., 1 Feb 2015, In: Molecular Genetics and Metabolism. 114, 2, p. 259-267 9 p.Research output: Contribution to journal › Article › peer-review
Open Access80 Scopus citations -
Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease
Shaaltiel, Y., Gingis-Velitski, S., Tzaban, S., Fiks, N., Tekoah, Y. & Aviezer, D., 1 Oct 2015, In: Plant Biotechnology Journal. 13, 8, p. 1033-1040 8 p.Research output: Contribution to journal › Article › peer-review
Open Access48 Scopus citations -
Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems
Tekoah, Y., Tzaban, S., Kizhner, T., Hainrichson, M., Gantman, A., Golembo, M., Aviezer, D. & Shaaltiel, Y., 2013, In: Bioscience Reports. 33, 5, p. 771-781 11 p., e00071.Research output: Contribution to journal › Article › peer-review
Open Access78 Scopus citations -
Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease
van Dussen, L., Zimran, A., Akkerman, E. M., Aerts, J. M. F. G., Petakov, M., Elstein, D., Rosenbaum, H., Aviezer, D., Brill-Almon, E., Chertkoff, R., Maas, M. & Hollak, C. E. M., Mar 2013, In: Blood Cells, Molecules, and Diseases. 50, 3, p. 206-211 6 p.Research output: Contribution to journal › Article › peer-review
31 Scopus citations -
Erratum: Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease (Blood (2011) 118:22 (5767-5773))
Zimran, A., Brill-Almon, E., Chertkoff, R., Petakov, M., Blanco-Favela, F., MuñOz, E. T., Solorio-Meza, S. E., Amato, D., Duran, G., Giona, F., Heitner, R., Rosenbaum, H., Giraldo, P., Mehta, A., Park, G., Phillips, M., Elstein, D., Altarescu, G., Szleifer, M., Hashmueli, S., & 1 others, 10 May 2012, In: Blood. 119, 19, p. 4577 1 p.Research output: Contribution to journal › Comment/debate
Open Access2 Scopus citations